Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension [artículo]
Por: Ruilope Urioste, Luis Miguel [Nefrología]
| Segura de la Morena, Julián [Nefrología].
Colaborador(es): Servicio de Nefrología.
Editor: Integrated Blood Pressure Control, 2011Descripción: 4:27-34.Recursos en línea: Solicitar documento Resumen: The majority of hypertensive patients, especially those with target organ damage, are likely to require multiple-drug therapy in order to reach blood pressure (BP) targets and reduce their risk of adverse vascular outcomes. The rationale for combination therapy with agents that block the renin-angiotensin system (RAS) and a calcium channel blocker (CCB) or diuretic is well founded in growing evidence. Recent published trials have shown that the combination of an RAS suppressor and a dihydropiridinic CCB would offer additional benefits independently of BP reduction. A telmisartan-amlodipine combination has demonstrated significantly greater BP reductions compared with each monotherapy component in the overall population, and in particular in patients with moderate to severe hypertension and high-risk patients. This combination is well tolerated with a safety profile similar to placebo and is consistent with the known safety profile of its monotherapy components.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC8449 (Navegar estantería) | Disponible |
Formato Vancouver:
Segura J, Ruilope LM. Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension. Integr Blood Press Control. 2011;4:27-34.
PMID:21949636
Contiene 55 referencias.
The majority of hypertensive patients, especially those with target organ damage, are likely to require multiple-drug therapy in order to reach blood pressure (BP) targets and reduce their risk of adverse vascular outcomes. The rationale for combination therapy with agents that block the renin-angiotensin system (RAS) and a calcium channel blocker (CCB) or diuretic is well founded in growing evidence. Recent published trials have shown that the combination of an RAS suppressor and a dihydropiridinic CCB would offer additional benefits independently of BP reduction. A telmisartan-amlodipine combination has demonstrated significantly greater BP reductions compared with each monotherapy component in the overall population, and in particular in patients with moderate to severe hypertension and high-risk patients. This combination is well tolerated with a safety profile similar to placebo and is consistent with the known safety profile of its monotherapy components.
No hay comentarios para este ejemplar.